Contra-indicated in patients without immunity to Epstein-Barr virus.
- TRADE NAME: Nulojix (Bristol-Myers Squibb)
- INDICATIONS: Prophylaxis of organ rejection in kidney transplantation
- CLASS: Immunosuppressant, T-cell co-stimulation blocker
- HALF-LIFE: 7–10 days
- FDA APPROVAL DATE: 06/15/2011
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Live vaccines, Mycophenolate
- See adverse reactions attributed to class:
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of belatacept in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
